+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Complement Inhibitors Market - Global Forecast 2026-2032- Product Image
Oral Complement Inhibitors Market - Global Forecast 2026-2032- Product Image
New

Oral Complement Inhibitors Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118495
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oral complement inhibitors market is undergoing significant transformation, driven by innovations that prioritize patient-centric solutions and streamlined clinical development processes. This report equips senior decision-makers with actionable knowledge to navigate the evolving landscape and capitalize on emerging commercial, operational, and regulatory opportunities.

Market Snapshot: Growth Trajectory of the Oral Complement Inhibitors Market

The Oral Complement Inhibitors Market grew from USD 2.20 billion in 2025 to USD 2.30 billion in 2026. It is expected to continue growing at a CAGR of 6.32%, reaching USD 3.38 billion by 2032.

Scope & Segmentation of the Oral Complement Inhibitors Market

This report delivers in-depth analysis across key segments and operational domains within the oral complement inhibitors industry. The structured approach supports development, access, and commercialization strategies.

  • Therapeutic Indications: Focus on rare and systemic diseases including Atypical Hemolytic Uremic Syndrome, Hereditary Angioedema, and Paroxysmal Nocturnal Hemoglobinuria.
  • Patient Cohorts: Segmentation across adult and pediatric populations, with targeted attention to age-specific dosing, safety follow-up, and disease profiles.
  • Mechanisms of Action: Emphasizes C1-directed therapies, molecular precision in complement cascade targeting, and implications for safety and translational advancement.
  • Geographic Regions: Analysis by Americas, Europe, Middle East & Africa, and Asia-Pacific, reflecting diverse regulatory, clinical, and payer infrastructures.
  • Commercial Strategies: Evaluation of decentralized care, telehealth-supported adherence, patient support programs, and operational execution partnerships.
  • Supply Chain Factors: Assessment of localization, multi-sourcing, tariff scenario planning, and mitigation of global distribution risks.

Key Takeaways: Strategic Insights on the Oral Complement Inhibitors Market

  • Oral complement inhibitors mark a shift towards patient-friendly administration, broadening access beyond infusion-dependent care settings.
  • Clinical development strategies now increasingly address real-world tolerability and logistics, not just efficacy and safety benchmarks.
  • Payer and regulatory dynamics are evolving—holistic value assessment incorporates patient-reported outcomes and resource utilization.
  • Companies leveraging decentralized trials, strong supply architecture, and real-world evidence secure advantages in speed-to-market and reimbursement discussions.
  • Segment differentiation—by indication, age cohort, and treatment strategy—enables precision in targeting unmet clinical needs.
  • Success depends on stakeholder alignment, operational proficiency, and patient-focused design across clinical and support services.

Tariff Impact: Navigating US Tariff Policies on Supply Chain and Commercial Outcomes

Recent and anticipated tariff actions in the United States present both operational and commercial challenges for oral complement therapeutics. Manufacturers and distributors may face elevated input costs, compelling reassessment of sourcing for active ingredients and packaging. In addition, supply chain localization and multi-sourcing strategies are emerging as key responses to safeguard margin integrity. Tariffs also influence negotiation dynamics with payers and distributors, as well as patient access programs—prompting manufacturers to introduce hedging arrangements and advanced logistics management. Treating tariff effects as a structural factor, rather than a short-term disruption, will position organizations to maintain continuity and mitigate downstream pricing pressures.

Methodology & Data Sources

This report employs a rigorous methodology integrating structured interviews with clinical experts, regulatory professionals, payers, and company executives specializing in complement biology. Secondary sources—peer-reviewed literature, regulatory guidance, and clinical trial databases—validate all segment analyses and strategic recommendations. Analytical processes focus on thematic triangulation and scenario planning to address both clinical and operational outcomes.

Why This Report Matters

  • Enables informed, proactive decision-making across clinical development, supply chain optimization, and commercialization planning in a fast-evolving market.
  • Supports strategic alignment for executive stakeholders by highlighting actionable levers in regulatory, operational, and partnership models.
  • Delivers clear, prioritized recommendations to advance pipeline development, secure regional access, and ensure supply chain resilience.

Conclusion

The oral complement inhibitors market demands integrated clinical, operational, and commercial strategies for effective patient impact. Organizations that unite translational evidence, strong supply infrastructure, and payer alignment are best positioned to accelerate adoption and deliver sustained value across global regions.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising preference for oral complement inhibitors in hereditary angioedema management strategies
5.2. Emergence of patient-centric digital adherence tools to support oral complement inhibitor regimens
5.3. Expansion of oral complement inhibitor clinical trials targeting geographic markets in Asia Pacific and Latin America
5.4. Strategic partnerships between biotech firms and pharma giants accelerating oral complement inhibitor commercialization
5.5. Healthcare payer negotiations intensifying over pricing and reimbursement of novel oral complement inhibitors
5.6. Integration of real-world evidence studies demonstrating long-term safety and efficacy of oral complement therapies
5.7. Advancements in molecular design improving selectivity and bioavailability of next-generation oral complement inhibitors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oral Complement Inhibitors Market, by Therapeutic Application
8.1. Introduction
8.2. Atypical Hemolytic Uremic Syndrome
8.2.1. Adult Patients
8.2.2. Pediatric Patients
8.3. Hereditary Angioedema
8.3.1. Acute Treatment
8.3.2. Prophylactic Treatment
8.4. Paroxysmal Nocturnal Hemoglobinuria
8.4.1. Adult Patients
8.4.2. Pediatric Patients
9. Oral Complement Inhibitors Market, by Mechanism Of Action
9.1. Introduction
9.2. C1 Inhibitors
10. Americas Oral Complement Inhibitors Market
10.1. Introduction
10.2. United States
10.3. Canada
10.4. Mexico
10.5. Brazil
10.6. Argentina
11. Europe, Middle East & Africa Oral Complement Inhibitors Market
11.1. Introduction
11.2. United Kingdom
11.3. Germany
11.4. France
11.5. Russia
11.6. Italy
11.7. Spain
11.8. United Arab Emirates
11.9. Saudi Arabia
11.10. South Africa
11.11. Denmark
11.12. Netherlands
11.13. Qatar
11.14. Finland
11.15. Sweden
11.16. Nigeria
11.17. Egypt
11.18. Turkey
11.19. Israel
11.20. Norway
11.21. Poland
11.22. Switzerland
12. Asia-Pacific Oral Complement Inhibitors Market
12.1. Introduction
12.2. China
12.3. India
12.4. Japan
12.5. Australia
12.6. South Korea
12.7. Indonesia
12.8. Thailand
12.9. Philippines
12.10. Malaysia
12.11. Singapore
12.12. Vietnam
12.13. Taiwan
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Analysis
13.3.1. Novartis AG
13.3.2. AstraZeneca PLC
13.3.3. BioCryst Pharmaceuticals, Inc.
14. ResearchAI
15. ResearchStatistics
16. ResearchContacts
17. ResearchArticles
18. Appendix
List of Figures
FIGURE 1. ORAL COMPLEMENT INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 10. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 12. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ORAL COMPLEMENT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 18. ORAL COMPLEMENT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 19. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHAI
FIGURE 20. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 21. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 22. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORAL COMPLEMENT INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 40. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 51. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 52. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 63. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 64. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 65. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 66. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 67. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 68. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 69. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 70. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 71. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 72. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 73. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 76. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 77. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 78. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 79. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 80. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 81. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 82. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 95. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 96. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 97. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 98. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 118. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 120. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 125. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 126. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 127. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 128. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 129. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 130. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 131. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 132. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 133. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 134. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 135. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 138. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 139. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 140. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 141. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 142. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 143. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 148. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 149. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 150. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 155. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 158. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 159. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 160. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 161. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 162. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 163. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 164. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 165. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 166. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 167. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 168. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 169. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 170. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 171. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 172. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 173. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 174. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 188. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 190. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 198. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 200. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 205. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 208. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 209. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 210. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 211. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 212. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 213. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 214. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 215. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 218. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 219. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 220. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 226. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 227. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 228. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 229. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 230. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 231. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 232. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 233. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 234. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 235. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 238. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 239. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 240. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 241. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 242. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 243. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 244. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 245. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 248. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 249. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 250. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 256. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 257. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 258. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 259. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 260. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 265. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 268. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 269. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 270. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 271. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 272. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 273. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 274. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 275. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 278. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 279. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 280. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 281. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 282. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 283. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 284. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 285. ISRAEL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 286. ISRAEL ORAL COMPLE

Companies Mentioned

  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Biocryst Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Omeros Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Swedish Orphan Biovitrum AB
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.3 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.38 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Complement Inhibitors Market - Global Forecast 2026-2032 - Product Image

Complement Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
C5 Complement Inhibitors Market Report 2025 - Product Image

C5 Complement Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Eculizumab Market - Global Forecast 2026-2032 - Product Image

Eculizumab Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Complement Inhibitors - Pipeline Insight, 2025 - Product Image

Complement Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 150 Pages
  • Global
From
Atypical Hemolytic Uremic Syndrome Treatment Market Report 2025 - Product Image

Atypical Hemolytic Uremic Syndrome Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.